News

One study questions the effectiveness of remdesivir past day 10 while others support its expanded use.

The COVID-19 pandemic has led payers and providers to embrace electronic encrypted documents and other technology — and that has fostered greater collaboration between them.

Findings presented at the European Society of Cardiology meeting could open the door to the use of the gout drug as a treatment targeting the underlying inflammation of cardiovascular disease.

This week's FDA updates include an end to a boxed warning for a type 2 diabetes drug, an expanded emergency use authorization due to COVID-19, and another liquid biopsy.

Georgetown’s Sabrina Corlette says the 2021 rates were calculated before the recent announcements about COVID-19 premium relief in this part two of two video series.

COVID-19 may have made clinician burnout even more of problem. AI could help by streamlining workflows.

The pharma maker will initially produce 150 million of the 5-minute tests.

Georgetown’s Sabrina Corlette explains some of the motivations behind the spate of premium credits and discounts from health insurers in this part one of two series.

Whether the online giant has larger healthcare ambitions is unclear.

But social distancing and face masks may mean less transmission of flu — and fewer colds.

But there are plenty of holdouts. Half of submissions are still done by phone or fax.

Integrated Benefits Institute study finds increased screenings for depression and detection of chronic conditions before symptoms present could have greatest impact on disability costs.

In this week’s episode of Tuning Into the C-Suite, Briana Contreras of MHE chatted with CEO of Interim HealthCare, Jennifer Sheets. She and Jennifer discussed how COVID-19 has impacted the demand for home care, how hospitals can partner with the operation and how new pursuits in healthcare will affect home care in the future.

SGLT2 inhibitors, GLP-1 receptor agonists also tackle cardiovascular disease, renal failure.

Senior Editor Peter Wehrwein speaks with Lou Ellen Horwitz, CEO of the Urgent Care Association, in this part two of two video series about centers that have not been paid yet for tests.

Results of an RCT of the coalition’s ‘hot spotting’ approach resulted in some reevaluation.

Biosimilars to Avastin and Herceptin are catching on.

Blue Cross and Blue Shield of Minnesota is among the health insurers giving businesses and individuals a break on premiums.

Scientists react negatively to FDA's handling of the Emergency Use Authorization for convalescent plasma in COVID-19.

Because COVID-19 has put the gesture in a different light, healthcare executives are coming up with other ways to greet people.

For opportunistic fraudsters and medical predators, the relaxation, suspension or outright elimination of restrictions on the use of telehealth technology presents a plethora of opportunities previously unseen.

FDA actions for the week ending August 21, 2020, include a hearing set for a drug that could limit weight gain often associated with treatment for serious mental illness.

Now is the time for compliance officers to get a better grasp on compliance and continuity across the organization.

Hospital room TVs have become interactive portals to a better patient experience.

Senior Editor Peter Wehrwein speaks with Lou Ellen Horwitz, CEO of th eUrgent Care Association, about how urgent care centers struggled to personal protective equipment and access to testing.

COVID-19 has revealed the power and value of data analytics as claims have gyrated in unprecedented ways.

Many providers are asking patients to wait in their cars. In the future, the waiting room could be divided into small, pod-like rooms.

An economic downturn will increase enrollment—and strain state budgets.